BioSpace News Archive

Aytu BioPharma, Inc. (the Company or “Aytu”) (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced financial and operational results for the quarter ended March 31, 2023.

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, announced its cash position as of March 31, 2023 and revenues for the first three months of 20231.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, reported financial results for the three and six months ended March 31, 2023 and provided an update on its business.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today reported its financial results for the quarter ended March 31, 2023 and provided a business update.

Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced the promotion of Michael Sherman Blue, M.D., FACEP to the position of Chief Medical Officer, reporting directly to the Company’s Board of Directors.

Theseus Pharmaceuticals, Inc. today announced business highlights and reported financial results for the first quarter ended March 31, 2023.

Intergalactic Therapeutics announced today that it will present two posters highlighting preclinical data for IG-002, Intergalactic’s lead program addressing all forms of ABCA4-related retinopathies, at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, being held in Los Angeles, CA, from May 16-20, 2023.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) today announced financial results for the first quarter 2023.

Extend Biosciences today announced positive results from its first-in-human trial of EXT608. An interim data analysis shows that EXT608 was safe and well tolerated, with no serious adverse events reported.

Bicycle Therapeutics plc (NASDAQ: BCYC) and Orano Med, two biotechnology companies respectively, announce pre-clinical results.